Sarepta Therapeutics (SRPT)

$20.72 +0.38 (1.87%)
Market Cap 2.13B
Revenue (ttm) 1.90B
Net Income (ttm) 235.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 7.71
Profit Margin 12.37%
Debt to Equity Ratio 0.78
Volume 1,869,900
Avg Vol 3,112,614
Day's Range N/A - N/A
Shares Out 104.79M
Stochastic %K 22%
Beta 0.48
Analysts Sell
Price Target $21.43

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dy...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 274 4000
Address:
215 First Street, Suite 415, Cambridge, United States
Thaigrlsrk
Thaigrlsrk Feb. 3 at 9:48 AM
$SRPT One of the best DMD doc's in the world tells her patients Elevidys is her go to recommondation. She said it in a presentation to DMD families. Roche doubled it's Elevidys sales. Sirolimus is being used on a regular basis already( says Dr. Proud). Six months has passed since the FDA try to kill Sarepta, the lines at the big clinics are filling. Mark my words by the end of this year It will be back to 3-4 B revenue progections.
0 · Reply
Martinsucks
Martinsucks Feb. 3 at 12:16 AM
$SRPT how is a stock that made 90 million have a market cap at 12 billion and this stock makes almost 500 million a qtr and has mc of 2 billion. Wtf?
1 · Reply
free2dream
free2dream Feb. 2 at 10:00 PM
$RMBS Another bullshit $13B valuation on 98M quarter. Even $SRPT pulls in $400M QUARTER AND ITS VALUED AT $2B . ABSOLUTELY IDIOTIC MARKET OERVALUING $SOX AND $SMH , TIME FOR A SERIOUS DEFLATION OF THAT SECTOR
1 · Reply
free2dream
free2dream Feb. 2 at 8:48 PM
$SRPT $SRRK $5B market cap on no sales ! Fxcking Sarepta is so ignored to the core. IDIOTIC $2B market cap on $2B sales. At some point this will soar to $100+ again. Idiotic to discount Elevidys. Absolutely idiotic. 25% short float, I want to see a gap open in $60S $XBI $LABU
1 · Reply
Martinsucks
Martinsucks Feb. 2 at 8:41 PM
$SRPT they just won't let this run eh? Why the wanna short this one constantly. Are they worried to let it run ?
1 · Reply
DeportedGreta
DeportedGreta Feb. 2 at 8:31 PM
$SRPT trash as always sells off
0 · Reply
obryanjfg
obryanjfg Feb. 2 at 5:55 PM
$SRPT Time for HCW to reinterate for the umpten-nth time.
1 · Reply
free2dream
free2dream Feb. 2 at 5:27 PM
$SRPT there arent many sellers left down here. We should retest $24 to move higher prior earnings announcement. The shorts are way complacent here at 25% short float. Sarepta will eventually return to $100+ , this is a terminal disease as AIDS WAS and Sarepta has proven that Elevidys slows the DMD progression and improve the childrens lives. IDIOTIC VALUATION AT ONLY $2B
1 · Reply
Dawnz
Dawnz Feb. 2 at 5:26 PM
$SRPT down 1%? Market acting like someone unplugged the gene therapy 😂
0 · Reply
free2dream
free2dream Feb. 2 at 5:20 PM
$SRPT heads up on $SRPT daily reversal , $XBI $LABU $SGMO ripping to $3 . Micro cap $MYO uptick !
0 · Reply
Latest News on SRPT
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript

Jan 26, 2026, 1:32 PM EST - 7 days ago

Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Jan 26, 2026, 8:53 AM EST - 7 days ago

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Jan 26, 2026, 8:10 AM EST - 7 days ago

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Jan 26, 2026, 8:00 AM EST - 7 days ago

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Jan 23, 2026, 4:05 PM EST - 10 days ago

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Sarepta Therapeutics: Is Elevidys A Bust?

Jan 16, 2026, 9:25 AM EST - 17 days ago

Sarepta Therapeutics: Is Elevidys A Bust?

Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 2:36 PM EST - 21 days ago

Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 11:58 AM EST - 21 days ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 12, 2026, 9:30 AM EST - 21 days ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 7, 2026, 8:30 AM EST - 26 days ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:30 AM EST - 4 weeks ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 31, 2025, 5:20 PM EST - 4 weeks ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests

Dec 17, 2025, 6:48 AM EST - 6 weeks ago

Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Dec 11, 2025, 7:00 AM EST - 7 weeks ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

Nov 25, 2025, 12:07 PM EST - 2 months ago

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 25, 2025, 8:57 AM EST - 2 months ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Nov 24, 2025, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 24, 2025, 7:30 AM EST - 2 months ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Nov 14, 2025, 5:48 PM EST - 2 months ago

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:54 PM EST - 2 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 14, 2025, 2:08 PM EST - 2 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Nov 4, 2025, 1:39 PM EST - 3 months ago

Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Nov 4, 2025, 12:33 PM EST - 3 months ago

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Nov 4, 2025, 12:11 PM EST - 3 months ago

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 9:55 AM EST - 3 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 6:20 AM EST - 3 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 5:36 AM EST - 3 months ago

Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 4, 2025, 4:27 AM EST - 3 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 6:26 PM EST - 3 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:24 PM EST - 3 months ago

Sarepta's Duchenne gene therapy misses main goal in study

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Nov 3, 2025, 4:05 PM EST - 3 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 27, 2025, 4:05 PM EDT - 3 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

Oct 23, 2025, 6:46 AM EDT - 3 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline

Oct 10, 2025, 11:49 AM EDT - 4 months ago

Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline

What's Going On Sarepta Stock On Wednesday?

Oct 8, 2025, 11:19 AM EDT - 4 months ago

What's Going On Sarepta Stock On Wednesday?

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Oct 3, 2025, 8:30 AM EDT - 4 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Sep 5, 2025, 9:00 AM EDT - 5 months ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 5 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Aug 25, 2025, 3:11 AM EDT - 5 months ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Aug 23, 2025, 7:08 AM EDT - 5 months ago

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

Aug 22, 2025, 12:12 PM EDT - 5 months ago

Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Aug 22, 2025, 9:50 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

Aug 21, 2025, 7:00 AM EDT - 5 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

Aug 20, 2025, 3:30 PM EDT - 5 months ago

SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman

Aug 18, 2025, 12:01 PM EDT - 6 months ago

Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman

Thaigrlsrk
Thaigrlsrk Feb. 3 at 9:48 AM
$SRPT One of the best DMD doc's in the world tells her patients Elevidys is her go to recommondation. She said it in a presentation to DMD families. Roche doubled it's Elevidys sales. Sirolimus is being used on a regular basis already( says Dr. Proud). Six months has passed since the FDA try to kill Sarepta, the lines at the big clinics are filling. Mark my words by the end of this year It will be back to 3-4 B revenue progections.
0 · Reply
Martinsucks
Martinsucks Feb. 3 at 12:16 AM
$SRPT how is a stock that made 90 million have a market cap at 12 billion and this stock makes almost 500 million a qtr and has mc of 2 billion. Wtf?
1 · Reply
free2dream
free2dream Feb. 2 at 10:00 PM
$RMBS Another bullshit $13B valuation on 98M quarter. Even $SRPT pulls in $400M QUARTER AND ITS VALUED AT $2B . ABSOLUTELY IDIOTIC MARKET OERVALUING $SOX AND $SMH , TIME FOR A SERIOUS DEFLATION OF THAT SECTOR
1 · Reply
free2dream
free2dream Feb. 2 at 8:48 PM
$SRPT $SRRK $5B market cap on no sales ! Fxcking Sarepta is so ignored to the core. IDIOTIC $2B market cap on $2B sales. At some point this will soar to $100+ again. Idiotic to discount Elevidys. Absolutely idiotic. 25% short float, I want to see a gap open in $60S $XBI $LABU
1 · Reply
Martinsucks
Martinsucks Feb. 2 at 8:41 PM
$SRPT they just won't let this run eh? Why the wanna short this one constantly. Are they worried to let it run ?
1 · Reply
DeportedGreta
DeportedGreta Feb. 2 at 8:31 PM
$SRPT trash as always sells off
0 · Reply
obryanjfg
obryanjfg Feb. 2 at 5:55 PM
$SRPT Time for HCW to reinterate for the umpten-nth time.
1 · Reply
free2dream
free2dream Feb. 2 at 5:27 PM
$SRPT there arent many sellers left down here. We should retest $24 to move higher prior earnings announcement. The shorts are way complacent here at 25% short float. Sarepta will eventually return to $100+ , this is a terminal disease as AIDS WAS and Sarepta has proven that Elevidys slows the DMD progression and improve the childrens lives. IDIOTIC VALUATION AT ONLY $2B
1 · Reply
Dawnz
Dawnz Feb. 2 at 5:26 PM
$SRPT down 1%? Market acting like someone unplugged the gene therapy 😂
0 · Reply
free2dream
free2dream Feb. 2 at 5:20 PM
$SRPT heads up on $SRPT daily reversal , $XBI $LABU $SGMO ripping to $3 . Micro cap $MYO uptick !
0 · Reply
Hardfocus
Hardfocus Feb. 2 at 5:06 PM
$SRPT Roche’s Genentech announced today a global licensing agreement with SanegeneBio, paying $200 million upfront to access a promising RNA interference (RNAi) program. Next up, SRPT
0 · Reply
jm0olah
jm0olah Feb. 2 at 5:06 PM
$SRPT shameless
0 · Reply
Maniacal_Laugh
Maniacal_Laugh Feb. 2 at 4:57 PM
$SRPT In December they significantly increased elevidys sales force. Q1 here could see a significant revenue increase. Roche is allready seeing real world growth and the ramp is just beginning. Its been years allready and they have 80% ambulatory patients left in usa. Growth here can go parabolic. Could be back over $100 with pt revisions shortly
0 · Reply
Maniacal_Laugh
Maniacal_Laugh Feb. 2 at 4:50 PM
$SRPT back to $25.00???
1 · Reply
Gladiator007
Gladiator007 Feb. 2 at 4:37 PM
$SRPT Last time it boumced back from here
1 · Reply
free2dream
free2dream Feb. 2 at 3:55 PM
$SGMO PATIENCE we are going to $3 $XBI $SRPT $NTLA $MYO
0 · Reply
free2dream
free2dream Feb. 2 at 3:54 PM
$LITE i was very bullish on this in the $40S and $50S but at this price it is extremely overvalued. Watch $AAOI that pulls the same shit every decade or so, runs up and drops back to single digits. Careful here, the upside here makes no sense, the market cap is already ridiculous at 31B on $1.8B sales. $SRPT has $2B sale and the market values it at $2B . The hot money chasing this to a bubble territory
1 · Reply
blueb22
blueb22 Feb. 2 at 3:44 PM
$SRPT - looks like Blackrock increased by 3m Shares - now 13.2 m!!! and Vanguard increased by 1m - now 11.8m. Good to see this. Let's see if there are other institutional buying in Q4 reported.
0 · Reply
Find_the_Cure
Find_the_Cure Feb. 2 at 3:34 PM
$SRPT it’s UP ⬆️ in case you didn’t look
0 · Reply
free2dream
free2dream Feb. 2 at 2:53 PM
$SRPT $RHHBY would be stupid not to act. They spent $1B just to help develop elevidys, niow they can have the entire company for $2B . Pure insanity. Reminds me of early Aids days, no cure but Sarepta can improve the childrens lives. Market is completely ignoring that. 400M quarter coming up and the market prices sarepta at $2B market cap is absolutely IDIOTIC.
0 · Reply
free2dream
free2dream Feb. 2 at 2:50 PM
$SRPT sarepta is srping loaded for a bounce at 25% short float it is about time. $XBI showing way more resilience than $SMH
0 · Reply
free2dream
free2dream Feb. 2 at 2:48 PM
$XBI nice bounce of the bottom of the channel $CLDX $SRPT $NTLA $SGMO
0 · Reply